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Abstract 
Objectives: In self reports, abstinent ecstasy/polydrug users claim that they experience 
certain ongoing affective and psychological changes including elevated anxiety, 
arousal and depression. In addition, various aspects of cognition (e.g. everyday 
memory, reasoning, executive functioning) appear to be affected. The present paper 
investigated the link between these two psychological sequelae. Methods: 95 
ecstasy/polydrug users completed tests of reasoning, intelligence, information 
processing speed, executive functioning, and everyday memory. Affect was measured 
via a mood adjective checklist. Adverse effects attributed to ecstasy were measured 
via responses to adjectives reflecting changes in users since they started using the 
drug. In addition, indicators of sleep quality and daytime sleepiness were obtained. 
Results: Users attributed a number of adverse effects to ecstasy, namely heightened 
irritability, depression, paranoia and deteriorating health. Adverse effects were 
significantly and negatively correlated with aspects of intelligence, everyday memory 
and sleep quality. Length of use of ecstasy use was positively correlated with adverse 
effects.  Conclusions: While many users attribute a number of adverse affects to their 
use of ecstasy it remains unclear whether these self perceptions are a corollary of the 
psychopharmacological effects of the drug or reflect factors which in fact predate its 
use. 
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The present research is concerned with those individuals who consume the 
street drug ecstasy, usually along with a range of other illicit substances. The main 
ingredient of ecstasy is 3, 4-methylenedioxymethamphetamine (MDMA). In a review 
of the literature, Parrott (2004) notes that since the late 1990s, in terms of 
psychoactive ingredients, chemical analysis reveals that most ecstasy tablets consisted 
of between 80-100% MDMA with the typical dose increasing during the first half of 
the present decade. Previous research from our laboratory has revealed that 
ecstasy/polydrug users are impaired on a range of cognitive measures compared to 
non-ecstasy using controls (Montgomery, Fisk, & Newcombe, 2005a; Montgomery, 
Fisk, Newcombe, & Murphy, 2005b; Montgomery, Fisk, Newcombe, Wareing & 
Murphy, 2005c; Montgomery, Fisk, Wareing & Murphy, 2007). However, it has 
sometimes proved difficult to establish a link between indicators of the level of 
ecstasy use (e.g. measures of lifetime use) and cognitive outcomes. It is possible that 
different patterns of drug taking may be associated with different levels of risk. For 
example, it may be the case that those persons who take ecstasy while engaging in 
excessive physical activity for prolonged periods of time in hot environments without 
adequately monitoring fluid intake are at particular risk from ecstasy-related 
neurotoxicity, (Parrott, Rodgers, Buchanan, Ling, Heffernan, & Scholey, 2006). 
Alternatively it may be the number of tablets typically taken on each occasion of use 
(Thomasius, Petersen, Buchert, Andresen, Zapletalova, Wartberg, et al. 2003) which 
determines the neurotoxic potential. Individual differences in enzyme regulated 
metabolic processes have also been implicated in adverse effects related to ecstasy use 
(Schifano, 2004).  It is clear that not all ecstasy users suffer adverse effects as a 
consequence of using the drug and there is no obvious way of determining which 
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users will exhibit performance deficits. One possible means of identifying those at 
risk may be to directly ask users whether or not ecstasy has had any adverse effects on 
different aspects of their behaviour. 
A number of studies have revealed that ecstasy/polydrug users report various 
adverse psychiatric and affective symptoms (e.g., Parrott, Buchanan, & Scholey, 
2002). What is less clear is whether or not these are a consequence of using ecstasy or 
whether they reflect some pre-existing disposition, or a combination of these two 
factors. For example, an individual may report themselves as being generally 
depressed (perhaps as a consequence of circumstances pre-dating ecstasy use) and use 
ecstasy as a form of self medication so as to temporarily improve their mood state. An 
additional explanation for self-reported ecstasy-related deficits may be that those 
individuals who volunteer to participate in studies of substance abuse do so because 
they already suspect (rightly or wrongly) that ecstasy might have harmed them in 
some way. Deficits may therefore be perceived rather than real (Bedi & Redman, 
2008). This self-selection bias might be because of exposure to press reports or other 
sources of information which purport to link drug use with adverse outcomes.  
It is also worthy of note that some researchers have failed to find evidence of 
increased psychopathology among ecstasy users. For example, while 40% of Murphy, 
Wareing, and Fisk’s (2006) sample reported an increase in adverse reactions, e.g., 
confusion, paranoia, and depression, since commencing ecstasy use, 42% actually 
reported a reduction in negative experiences. Morgan (1998) found no differences in 
self-reported mood, anxiety, and aggression, between ecstasy users, polydrug controls 
and non-drug users and Dafters, Duffy, and O’Donnell (1999) found that there was no 
relationship between the amount of ecstasy consumed during the previous 12 months 
and measures of depression and positive and negative affectivity. Furthermore 
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Thomasius et al (2003) reported that adverse symptoms were associated with 
polydrug use in general rather than specifically ecstasy use. Similar findings were 
reported by Bedi, Van Dam and Redman (2008) who also note that responses to self-
report checklists may reflect transient sub-acute post-intoxication effects rather than 
clinically significant psychiatric problems. Findings from another recent study which 
utilised a longitudinal design revealed that while a positive association existed 
between self reported depression and lifetime ecstasy use, the levels reported were not 
clinically significant and declined in both current and abstinent ecstasy users over a 24 
month period (Falck, Wang & Carlson, 2008). 
Nonetheless, a number of studies using self-report measures do report adverse 
ecstasy-related effects.  Parrott and Lasky (1998) observed that two days after 
consuming ecstasy, users were more depressed, unsociable, and ill-tempered, 
compared to nonusers. Ecstasy users also felt more abnormal and experienced 
unpleasant feelings to a greater degree than controls. Relative to controls, Curran and 
Travill (1997) reported that while ecstasy users exhibited an elevated mood state on-
drug, five days later they exhibited mood impairment and heightened depression. 
Similarly, Gamma, Buck, and Berthold (2001) found that ecstasy users were more 
depressed relative to nonusers and more recently a longitudinal study revealed that 
they exhibited elevated anxiety, obsessive/compulsive tendencies and impaired 
interpersonal sensitivity on the SCL-90 measure (Thomasius, Zapletalova, & 
Petersen, 2006). These deficits were evident in both current and former ecstasy users 
and persisted over the duration of the study. 
 Parrott et al’s (2002) ecstasy-using respondents indicated that they had 
suffered depression, memory problems, anxiety, mood fluctuation, poor 
concentration, and physical problems (infections, tremors/twitches and weight loss) as 
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a consequence of their ecstasy use. The likelihood of reporting symptoms increased 
with the extent of ecstasy use. Ecstasy users were also found to be significantly more 
depressed compared to controls in a study by McCardle, Luebbers, and Carter (2004) 
and more recently, Lamers, Bechara, and Rizzo (2006) found that relative to cannabis 
only and drug naïve controls, ecstasy/polydrug users were significantly more 
depressed and exhibited higher levels of anxiety. Finally, Curran, Rees, and Hoare 
(2004) and Hoshi, Pratt, and Mehta (2006) found that ecstasy users were more likely 
to attribute aggressive meanings to ambiguous sentences compared to nonusers. 
Relatively few studies have examined the mediating role of psychological 
affect in underpinning ecstasy-related cognitive deficits. McCardle et al (2004) found 
that ecstasy-related deficits in recall remained statistically significant following 
statistical controls for group differences in depression. However, it remains unclear 
whether the adverse emotional and affective changes specifically attributed to ecstasy 
use are associated with adverse outcomes in other aspects of cognition. 
To summarise, there is evidence for ecstasy-related impairment in aspects of 
psychological affect and psychological health (e.g., Parrott et al, 2002) which in some 
instances co-occurs with deficits in aspects of cognition (Thomasius et al, 2006). 
Adverse psychopathology is not always evident (Bedi & Redmond, 2008) nor are 
cognitive deficits always found (McCardle et al, 2004). It is apparent therefore that 
adverse outcomes are not present in all ecstasy users and it may be that those who 
self-report adverse effects arising from ecstasy use in aspects of mood, concentration, 
and emotional expression may be the same group who experience cognitive and other 
deficits.  Aside from the evidence that psychiatric conditions such as schizophrenia 
are associated with specific forms of cognitive impairment, it has also been 
documented that sub-clinical levels of depression and anxiety are associated with 
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cognitive impairment (e.g. Ramponi, Barnard, & Nimmo-Smith, 2004; Sedek & von 
Hecker 2004).  It may be that ecstasy-related deficits in cognition and affect are 
concentrated among those who self-report adverse effects of using the drug.  
Therefore, various cognitive and affective measures were analysed including those 
where ecstasy-related deficits have previously been observed in order to establish 
whether scores on these were negatively related to the number of self-reported 
adverse reactions to the drug.  
It was predicted that indicators of recent and longer term ecstasy use would be 
positively related to the number of adverse reactions. No association between the use 
of other drugs and self-reported adverse reactions to ecstasy was predicted. Adverse 
reactions were predicted to be negatively associated with performance in other aspects 
of cognition including intelligence, memory, and executive functioning. Adverse 
reactions were also predicted to be associated with diminished psychological affect, 
impaired general health and sleep quality, and psychophysiological measures 
including arousal. 
Method 
 
Design 
Correlational analysis is used with the number of adverse ecstasy-related effects 
reported being correlated with respectively, recent and longer term patterns of drug 
use, indicators of intelligence, aspects of executive functioning, measures of day time 
sleepiness and physiological arousal, aspects of  psychological affect and everyday 
memory functioning. Since predictions are directional in nature, one-tailed probability 
values are reported. 
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Participants 
This study makes use of an existing database that was constructed over the period 
2002 to 2007. The database includes 95 ecstasy/polydrug users (53 males, 42 females; 
mean age 21.56, S.D. 1.92), individuals who currently use or who have previously 
used ecstasy. In terms of illicit drugs, three participants had used only ecstasy, a 
further 17 had used ecstasy and one other drug, while the remainder were polydrug 
users in the sense that they used ecstasy along with two or more of the following: 
cocaine, cannabis, and amphetamine. This database enabled us to explore differences 
between ecstasy users and nonusers in a range of cognitive functions and the results of 
this research have been reported elsewhere (e.g., Montgomery et al 2005a; 2005b; 
2005c; 2007). However, we have never before examined how self perceptions among 
abstinent users regarding the effects of their ecstasy use, relate to outcomes on other 
important psychological constructs and that is the purpose of the present paper. The 
participants whose data are included in our database were recruited via direct 
approach to university students, and by the snowball technique. Participants were 
requested to refrain from ecstasy use for at least 7 days prior to testing and were also 
requested not to use any other illicit drug for at least 24 hours prior to testing. Mean 
lifetime ecstasy dose is 328.02 tablets (SD 415.68) and mean frequency of use 0.39 
times per week (SD 0.44), although at the time of testing 21 users were long term 
abstinent (no use in last 6 months).  
 
Materials/ Measures 
Measures of Intelligence and Processing Speed. Analogical reasoning was 
assessed via word pair analogies (based on the SATS analogy quiz). Participants are 
presented with two capitalised words (e.g. MASON: STONE), and the five possible 
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answers in which the one of the word pairs reflected a similar analogy (e.g. Carpenter: 
Wood). There are 30 items and participants receive a total score for the number of 
analogies correctly inferred from the word pairs.  
Fluid intelligence was measured via Raven’s Progressive Matrices (Raven, 
Raven, & Court, 1998), and premorbid intelligence was assessed via the National 
Adult Reading Test (NART- Nelson, 1982).  The processing speed task involves the 
comparison of pairs of stimuli with the participant required to determine whether the 
pairs were the same or different as quickly as possible (see Wareing, Fisk, 
Montgomery, Murphy, & Chandler, 2007 for a complete description). Processing 
speed has been associated with intelligence scores with fast processors typically 
scoring higher on intelligence tests (e.g., Stough, Nettelbeck, Cooper, & Bates, 1995).  
Measures of Executive Functioning (see Montgomery et al 2005b for full 
descriptions).  
Measures of the separable components of executive functioning were 
administered relating to the updating, switching, access, and inhibition component 
processes (Fisk & Sharp, 2004). Computation span is an indicator of the updating 
component process and involves the serial recall of digit sequences. The sequences 
are presented simultaneously with a dual task. Participants achieve a span score 
analogous to digit span which corresponds to the maximum number of digits recalled 
in the correct order subject to the requirement that the dual task is completed without 
error. 
Letter updating involves presenting participants with sequences of consonants 
which vary in length (four different sequence lengths are used). In each trial the 
participant is unaware of the number of letters that will be presented. The task is 
 10 
tailored to the participant’s span, such that at the end of each sequence they are asked 
to recall ‘n’ letters, where ‘n’ is equal to their span (i.e., 4, 5, or 6 letters).  
Two tasks measure the switching component of executive functioning. In the 
plus-minus task participants solve a number of simple arithmetic problems alternating 
between addition and subtraction. In the number letter task, participants alternately 
classify number letter pairs as vowel/consonant or odd/even.  
The Chicago Word Fluency test is believed to measure the efficiency of access 
to semantic memory. Within fixed time limits, participants write down as many words 
as possible beginning with the letter S and as many four letter words beginning with 
the letter C. Semantic fluency is administered in a similar manner except that 
participants are asked to produce as many animal names as possible. 
In the random letter generation task participants are asked to produce letters in 
a random sequence by imagining that they are drawing the letters of the alphabet from 
a hat, speaking each letter produced aloud and then replacing it and repeating the 
procedure. The task is repeated three times with letters produced at 4, 2, or 1 second 
intervals and is believed to load on the inhibition executive component process. 
These measures of executive functioning have been used extensively in the 
past (see for example, Fisk & Sharp, 2004). 
Real World Memory Measures (see Fisk & Montgomery, 2008, for full 
descriptions). 
Four self-report real-world memory measures were administered. The 
Everyday Memory Questionnaire (EMQ; Sunderland, Harris, & Baddeley, 1983) is a 
self-report measure of memory lapses in everyday activities. The Cognitive Failures 
Questionnaire (CFQ; Broadbent, Cooper, FitzGerald, & Parkes, 1982) measures the 
prevalence of attentional lapses in everyday contexts. The Cognitive Failures 
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Questionnaire for Others is completed by the participant’s ‘significant other’ and 
assesses the extent to which that person believes that the participant exhibits 
attentional lapses. Prospective memory is assessed using the Prospective Memory 
Questionnaire (PMQ), (Hannon, Adams, Harrington, Fries-Dias, & Gipson, 1995). 
The PMQ provides measures of three aspects of PM short-term habitual PM, long-
term episodic PM, and internally cued PM. In addition, 14 questions make up the 
“techniques to remember” scale, which provides a measure of the number of strategies 
used to aid remembering. The reliability and validity of the CFQ, EMQ and PMQ 
have been documented previously (see, for example, Hannon et al, 1995; Royle & 
Lincoln, 2008; Wallace, 2004). 
Measures of Sleep Quality and Wakefulness.  
The Epworth Sleepiness Scale (ESS) measures the likelihood of dozing off 
during the day in various situations (Johns & Hocking, 1997). The Karolinska 
Sleepiness Scale (KSS; Gillberg, Kecklund, & Akerstedt, 1994) measures the 
participant’s state of sleepiness at a given moment in time. The remaining questions 
set out below assessed various aspects of sleep quality. No specific time frame was 
specified in relation to these.  Thus they reflect general perceptions. 
 The sleep type indicator assesses the extent to which individuals view 
themselves as morning types or evening types. Participants read the following 
statement: “We hear about people who ‘feel better in the morning’ or who ‘feel better 
in the evening’. Which of these two types do you think you are?” Participants respond 
by selecting one of the following alternatives scored 1 to 5 respectively: A. definitely 
a ‘morning’ type; B. more ‘morning’ than ‘evening’; C. neither one nor the other; D. 
more ‘evening’ than ‘morning’; E. definitely an ‘evening’ type. 
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 Sleep quality is assessed by the following question: “How well do you 
normally sleep at night?”  Participants respond by selecting one of the following 
alternatives scored 1 to 4 respectively: A. very well; B. satisfactorily; C. not very 
well; D. very badly. 
 Morning tiredness is assessed by the following question: “How refreshed do 
you usually feel in the mornings?” Participants respond by selecting one of the 
following alternatives scored 1 to 4 respectively: A. very alert; B. fairly alert; C. fairly 
tired; D. very tired. 
Psychological Affect 
Mood adjective checklist: Anxiety, depression/hedonic tone, and arousal are 
measured by means of a mood adjective checklist (see Matthews, Jones, & 
Chamberlain, 1990; Wareing, Fisk, & Murphy, 2000). Of the 18 words on the 
checklist, six words map onto each of these three constructs. For each word 
participants rate themselves as either: not at all, slightly, moderately, very, or 
extremely, with high scores indicative of higher levels of perceived arousal, anxiety, 
and depression. 
Drug Use 
Patterns of drug use and other relevant lifestyle variables are investigated via 
means of a background questionnaire (Montgomery et al, 2005b; Murphy et al, 2006). 
Ecstasy users are asked if they believe that since using ecstasy they have changed in 
any way. They respond to each of the following words: caring (-), paranoid (+), alert 
(-), depressed (+), sociable (-), aggressive (+), happy (-), healthy (-), moody (+), 
patient (-), irritable (+), confident (-), sad (+), loving(-), and confused (+), using a five 
point scale: much more 5, more 4, no change 3, less 2, and much less 1. The number 
of words eliciting adverse reactions is calculated. Responses of 4 or 5 to words 
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suffixed with (+) constitute an adverse reaction as do responses of 1 or 2 to words 
suffixed with (-). Ecstasy users are also asked to respond ‘Yes’ or ‘No’ to the 
following questions: ‘Do you take any sort of precautions when using ecstasy?’, 
‘When under the influence of ecstasy do you take rest breaks when dancing?’, ‘When 
under the influence of ecstasy do you monitor your fluid intake?’, and ‘Is there a 
maximum number of ecstasy tablets you will take in one session?’ 
In relation to drug use, participants are asked a range of questions including 
duration of use, and the last time that they had used each drug. Participants are also 
questioned concerning their history of drug use, i.e., when they began taking specific 
illicit drugs and the last occasion when each drug was consumed. The amount 
consumed of each drug during the previous 10 and 30 days is also assessed. 
Participants also indicate the number of different illicit drugs that they had previously 
consumed. 
Procedure 
Participants are informed of the general purpose of the studies, and written 
informed consent is obtained. The tasks are administered under laboratory conditions, 
and a computer running MS-DOS is used for the computer based tasks. Participants 
are fully debriefed, paid £20 in store vouchers, and given drugs education leaflets. 
The studies were approved by the Liverpool John Moores University Research Ethics 
Committee, and were administered in accordance with the ethical guidelines of the 
British Psychological Society. 
Results 
The average number of reported adverse reactions was 2.89 (s.d. 2.86). The 
median was 2 and the range was 0 to 11. While kurtosis was not a problem, z=0.11, 
p>.05, the distribution was severely positively skewed, z=3.83, p=.0001. Following 
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transformation (taking the inverse), skewness was reduced but remained problematic, 
z=2.97, p=.0015. For this reason non parametric tests were used. Twenty six percent 
of the sample reported no adverse effects, 27% one or two, 21% three or four, and 
25% five or more adverse effects. Inspection of Table 1 reveals that a substantial 
proportion of the sample indicated that ecstasy had made them more paranoid and/or 
less healthy (over 40% in both cases), over 30% in each case indicated that ecstasy 
had made them more moody and/or more irritable, and over 20% less patient and/or 
more confused. In all of these cases, the other users predominantly reported no change 
and there were only one or two users reporting positive changes. However on some of 
the other aspects of behaviour substantial number of users reported positive outcomes, 
for example that ecstasy had made them more caring, sociable, happy, and confident. 
While cumulatively almost half of the participants reported three or more adverse 
effects, it is noteworthy that the modal response to each individual question was ‘no 
change’. 
Examination of Table 2 reveals that there was no significant relationship 
between the number of reported adverse ecstasy-related effects and the amounts of the 
various illicit drugs consumed during the previous 10 days (although in two cases the 
correlations were associated with p values of .053 and .063). Among those ecstasy 
users who smoked tobacco there was a positive correlation between the number of 
cigarettes consumed in the previous 10 days and the number of adverse reactions 
reported. There was no association between the amount of various illicit drugs 
consumed within the previous 30 days and reported adverse reactions. Inspection of 
Table 3 reveals that there was a positive association between the length of ecstasy use 
and reported adverse reactions. The period of abstinence for various illicit drugs was 
unrelated to reported adverse reactions. However, the association between the number 
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of reported adverse reactions and the period of abstinence from cannabis use was 
associated with a probability of .065.  
Measures of intelligence (Ravens progressive matrices and analogical 
reasoning) were significantly and negatively related to the reported number of adverse 
reactions associated with ecstasy use (see Table 4). Emotional intelligence was also 
negatively related to the number of reported adverse reactions. However, this 
relationship has been explored in depth in other research from our laboratory (Craig, 
Fisk, Montgomery, Murphy, & Wareing, in press) and will not be discussed further 
here. The association between the number of errors on the processing speed task and 
the number of reported adverse reactions although nonsignificant was associated with 
a probability of .057, with those reporting more adverse reactions committing more 
errors. None of the measures of executive functioning were significantly associated 
with the number of reported adverse reactions, although the association between one 
of the measures of the switching component executive process and the number of 
adverse reactions produced a probability of .064. Those reporting more adverse 
reactions exhibited a larger switch cost (indicative of a greater degree of impairment). 
However, the association with the other measure of the switching process was not 
significant. 
Inspection of Table 5 reveals that reported adverse reactions to ecstasy were 
significantly associated with short-term prospective memory (PM) problems. 
Furthermore, the number of reported adverse effects was positively correlated with 
everyday memory problems and also with the number of techniques used to aid PM 
recall. While in both cases the relationships were not statistically significant, they 
were associated with probability values of .060 and .063 respectively. The outcomes 
evident in Table 6 demonstrate that higher levels of reported adverse effects are 
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associated with sleep problems. High scores on the Karolinska, Epworth, sleep quality 
and morning alertness measures are indicative of sleep problems. Thus the positive 
correlation between these measures and the number of reported adverse effects 
indicated that those reporting more adverse effects were subject to impaired sleep and 
increased daytime tiredness. Indeed over 20% of the present sample had a score of 10 
and above on the Epworth measure which is consistent with clinical levels of sleep 
impairment. Aside from increased daytime sleepiness, those reporting more adverse 
effects also had significantly lower levels of self-reported physiological arousal and in 
terms of their present state-of-mind, they described themselves as significantly more 
anxious and depressed. 
Discussion 
 
 The present study assessed a range of adverse effects reported by users of 
ecstasy. It was found that ecstasy users reported certain psychological changes, which 
they attributed to their ecstasy use. Use of ecstasy was associated with increased 
paranoia, deteriorating health, heightened depression, increased moodiness and 
irritability, impatience and confusion. Some aspects of intelligence, real world 
(prospective) memory function, and general psychological affect (state anxiety and 
depression) also appear to be subject to a greater degree of impairment among those 
users reporting more adverse reactions. There was also a significant positive 
correlation between tobacco use and reported adverse effects indicating that as 
adverse effects increased, so did amount of tobacco consumed in the previous 10 
days.   
 The types of adverse effects noted in the present study have been associated 
with cognitive deficits in other populations. For example, non-ecstasy using depressed 
individuals frequently exhibit memory impairments (e.g. Austin, Mitchell & 
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Goodwin, 2000). Thus it may be that ecstasy causes adverse effects, which in turn 
cause prospective memory failures, anxiety and depression. While it is possible that 
these affective states might have preceded the use of the drug, in the present case, our 
participants specifically attributed them to ecstasy use. Therefore the present results 
raise the possibility that ecstasy use gives rise to adverse reactions in some users 
which may in turn cause them to report elevated levels of depression and anxiety as 
well as memory impairment. However, due to our reliance on self-reports and the 
retrospective nature of our study, it is not possible to make a definitive statement in 
this regard. 
The incidence of reported adverse effects supports previous research where 
ecstasy has been implicated. For example, Parrott and Lasky (1998) reported elevated 
depression and irritability; Curran and Travill (1997) likewise reported mood 
impairment and elevated depression. Curran et al. (2004) also reported increased 
perceived aggression following ecstasy use. However, the present study differs from 
previous research as the adverse effects reported by the ecstasy users were directly 
attributed to their ecstasy use. In addition, the median abstinence period was 3 weeks, 
with ¼ of the sample reporting abstinence for six months or more, indicating that 
these adverse effects are likely to persist for longer periods of time. The persistence of 
reported adverse effects might indicate that ecstasy use produces lasting changes to 
these aspects of behaviour. However, other possibilities must be acknowledged, for 
example, it may be that the individuals in question exhibit underlying 
psychopathology which possibly predates ecstasy use and which they mistakenly 
attribute to the drug. 
 Also worthy of note was the significant correlation between length of ecstasy 
use and adverse effects indicating that adverse effects increased with increasing length 
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of use. Other studies looking at various negative consequences of ecstasy use (e.g. 
adverse effects on memory) have found that length of use is an important factor. For 
example in a longitudinal study, Zakzanis and Young (2001) found that continued 
administration of ecstasy use over a 1-year period was associated with a decrease in 
memory performance. Similarly Croft, Klugman, Baldeweg, and Gruzelier (2001) and 
Wareing et al. (2000) found that long-term users of ecstasy are at particular risk of 
brain and cognitive dysfunction respectively.   
Time since last use of ecstasy showed no relationship to reported adverse 
effects. This is consistent with the possibility that the adverse effects are an enduring 
consequence of using the drug rather than a sub-acute transient effect. However, the 
absence of a significant association between the period of abstinence and reported 
adverse effects might also be consistent with the possibility that they reflect some 
underlying psychopathology predating ecstasy use and mistakenly attributed to the 
drug. As for the other drugs that were considered, with one exception there was no 
significant correlation between time since last use and ecstasy-related adverse effects. 
The exception was cannabis where a negative correlation between adverse effects and 
time since last use was very close to significance. This is consistent with a significant 
reduction in anxiety over time since last cannabis use we have reported in another 
sample (Murphy, Erwin, Wareing, Blackman, Yanulevitch, Keane, et al, 2008). 
 The statistically significant correlation between adverse effects and amount of 
tobacco smoked in the last 10 days could be explained in a number of ways. It may be 
that those ecstasy users who are experiencing adverse effects smoke more to alleviate 
their symptoms. Alternatively, it may be that the use of tobacco actually exacerbates 
the adverse effects experienced. Smoking has been found to be highly comorbid with 
clinical and sub-clinical anxiety and depression: two of the adverse effects noted in 
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the present study. However it remains unclear whether smoking is a response to, or a 
cause of, these other factors (Gilbert & Gilbert, 1995; Morrell & Cohen, 2006; Parrott 
& Kaye, 1999; Parrott, Morinan, Moss, & Scholey, 2004). Nicotine may be associated 
with heightened or diminished anxiety depending on the sub-type and neural location 
of particular nicotinic (nAChR ) receptors, whether the effects of nicotine treatment 
are to activate or desensitize these receptors, and the knock-on effects on the major 
neurotransmitters including dopamine. Thus whether outcomes are anxiogenic and 
anxiolytic is believed to depend on the specific neural pathways that are implicated 
(Picciotto, Brunzell, & Caldarone, 2002) and in the present context the situation is 
further complicated by the direct pharmacological action of ecstasy on serotonergic 
and dopaminergic systems. Therefore outcomes may be variable and finely balanced 
depending on the combined effects of MDMA and nicotine on specific neural 
pathways. 
While the specific neuropsychopharmacological mode of action remains 
uncertain, it is clear that individuals do smoke to alleviate feelings of anxiety and 
depression. For example, sensitivity to anxiety-related symptoms (i.e., perceiving 
them as indicative of a loss of control and illness) may predispose individuals to 
smoking and it has been argued that despite its effects on physiological arousal, 
subjectively, nicotine has anxiolytic properties for those exhibiting anxiety sensitivity 
(Stewart, Karp, Pihl, & Peterson, 1997). Scheitrum and Akillas (2002) have proposed 
that smoking is a form of self medication which can have stimulatory or anxiolytic 
properties depending on the individual’s personality and their underlying level of trait 
anxiety. Thus within this broader context, the results reported here are consistent with 
the possibility that users in the present sample smoked to alleviate the ecstasy-related 
adverse effects that they were experiencing.  
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Nonetheless, the possibility that smoking was a response to some pre-existing 
depressed or anxious state or that cigarettes were somehow directly responsible for 
the negative feelings experienced by users cannot be excluded. If this were the case 
then users might possibly misattribute their adverse reactions to ecstasy use when in 
fact they were pre-existing or due to the effects of nicotine. However, we re-examined 
the relationship between reported adverse effects and anxiety and depression 
excluding all those ecstasy users who smoked cigarettes. Although this reduced the 
sample size to just 30 participants (thereby increasing the likelihood of a Type 2 
error), the correlations between adverse reactions and the two affect measures 
remained statistically significant, r = .344 and r = .332 for anxiety and depression 
respectively, p<.05 in both cases. Thus it appears that the positive association between 
reported adverse effects and respectively depression and anxiety is not limited to 
ecstasy users who consume nicotine but is also prevalent among non smoking ecstasy 
users. 
An additional finding emerging from our results was the association between 
ecstasy related adverse effects and reported sleep problems. Research suggests that 
the chronic use of ecstasy causes sleep disturbances and sleep deprivation (Baylen & 
Rosenberg, 2006; Montoya, Sorrentino, Lukas, & Price, 2002). In the present study 
the adverse effects attributed to ecstasy use were significantly associated with 
reported sleep problems and with depressed mood. Sleep deprivation has itself been 
associated with negative affect in a recent human study. Those who were sleep 
deprived experienced significantly greater negative outcomes in relation to subjective 
vigour, fatigue and depression (as assessed by the Profile of Mood States 
questionnaire). Furthermore, relative to those who were simply sleep deprived, those 
who were both sleep deprived and required to perform moderate intermittent exercise 
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during the period of deprivation were found to be particularly prone to negative mood 
disturbance (Scott, McNaughton, & Polman, 2006). Again the association between 
negative mood, sleep deprivation and exercise would appear to be especially relevant 
to ecstasy users given the particular circumstances in which the drug is consumed. 
In the sleep literature individuals have been classified according to whether 
they see themselves as morning or evening types (Horne & Ostberg, 1976). In a recent 
study, Selvi, Gulec, Agargun, and Besiroglu (2007) found that morning types were 
more susceptible to adverse mood effects (depression) following sleep deprivation 
with evening types showing no adverse mood effects. In the present study however, 
morningness-eveningness was not significantly correlated with the adverse effects 
associated with ecstasy. Thus, it appears that the adverse effects that were prevalent 
among users and the negative mood states associated with them are not mediated or 
exacerbated by this aspect of sleep type.  
 In our previous research we have documented a number of instances where 
ecstasy/polydrug users exhibited performance decrements relative to non ecstasy users 
(Montgomery & Fisk, 2007; Montgomery et al 2005b; 2007). If these deficits were 
more evident in those users who reported adverse effects then in the present sample it 
might expected that a significant correlation would exist between self-reported 
adverse effects and scores on those measures where deficits have been previously 
documented. This expectation was supported by the significant correlations with some 
measures of function (e.g. prospective memory, depression, anxiety, arousal, sleep 
quality). However, there was no significant correlation between previously well 
documented (e.g. updating- Montgomery et al. 2005b) decline in aspects of executive 
function and adverse effects. Conversely, areas where we have not previously 
documented differences between ecstasy polydrug users and nonusers were 
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significantly correlated with adverse effects (e.g. aspects of intelligence). It is unclear 
why this dissociation occurred and clearly further research may be needed to shed 
light on these contrasting outcomes. It may be that those apparent ecstasy-related 
deficits which occur independently of reported adverse effects are not actually a 
consequence of ecstasy use but perhaps reflect some pre-existing difference between 
users and nonusers which has its origins before the initiation of drug use. Consistent 
with this possibility, in the context of the longer term consequences of cannabis use 
Pope (2002) has emphasised the importance of considering whether or not the 
apparent differences between users and nonusers might reflect pre-morbid conditions 
perhaps in sociodemographic factors, personal dispositions, or underlying 
psychopathology. 
 There were a number of limitations to the present study. As with much 
research in this area we relied on self-reports to confirm recent use/abstinence. 
Similarly, we asked individuals to estimate their use of various drugs and clearly 
individuals may have been inaccurate when reporting these values. Due to constraints 
on resources it was not possible to resort to physiological testing methods such as hair 
analysis, urinalysis or breathalysers. While this would have been preferable, it is 
commonplace in research among ecstasy users to rely on self report measures (e.g. 
Fox, McLean, Turner, Parrott, Rogers, & Sahakian, 2002; Morgan 1999). 
Nonetheless, even if our participants were accurate in their self reports, it is possible 
that recent use may have in someway affected their responses. For example, Pope, 
Gruber, Hudson, Huestis, & Yurgelun-Todd (2001) have noted that residual amounts 
of cannabinoids remain present in the system for up to 30 days after the last use of 
cannabis. 
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A further limitation was the use of the snowball method of recruitment. While 
this is common among researchers operating in the substance abuse area (e.g., 
Solowij, Hall, & Lee, 1992) it does have its limitations. First it is open to self-
selection bias in the sense that those users who are willing to participate in research of 
this kind may not be representative of users in general. Second, a condition of ethical 
approval for the study was that users would be properly informed, debriefed and 
provided with drug education leaflets. While the information provided was generally 
neutral in tone, and the information sources listed generally adopted a harm reduction 
approach, it was stated that the experimenters did not condone the use of illicit drugs. 
Furthermore it was stated that the purpose of the study was to establish whether illicit 
drug users performed differently on various measures and the extent to which any differences 
observed were attributable to ecstasy or to the effects of other drugs. While we did not 
explicitly mention deficits or impairment the information provided may have 
encouraged participation from those persons who were already concerned about 
aspects of their use (Bedi, & Redman, 2008).  
For example, as a direct result of reading about the background to our 
research, or through prior exposure to negative information sources in the media or 
via friends and personal contacts, users may have approached our study with the 
preconception that ecstasy is harmful. These expectations may have affected the 
responses that were produced with users endorsing adverse effects not because they 
actually experienced them but because they believed that they should. Alternatively 
they may have misattributed pre-existing or unrelated conditions to ecstasy use. Cole, 
Michailidou, Jerome, & Sumnall (2006) have demonstrated that inducing such 
stereotype threat may actually cause users to perform worse on cognitive measures. 
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Thus again given our method of recruitment our sample may not have been 
representative of ecstasy users in general. 
In summary, the present paper found that ecstasy/polydrug users reported a 
range of adverse psychological effects which they attributed to ecstasy use. These 
adverse effects were significantly correlated with length of use of ecstasy raising the 
possibility that adverse effects are a long-term consequence of using the drug. Future 
research should seek to further investigate the link between reported adverse effects 
and measures of psychological functioning. In the present paper executive function 
measures were not correlated with adverse effects while some everyday memory 
measures, and some mood measures were. Thus future research should seek to 
elucidate this link while at the same time attempting to address some of the 
methodological limitations evident in research of this kind. 
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Table 1 
 
Number of ecstasy users indicating changes in behaviour 
 
 
Ecstasy has 
made me: 
Much 
Less 
Less No 
Change 
More Much 
More 
Caring 0 3 73 16 3 
Paranoid 1 2 53 35 4 
Alert 1 15 71 6 2 
Depressed 0 2 66 25 2 
Sociable 0 3 43 41 8 
Aggressive 2 6 76 9 2 
Happy 0 8 66 16 5 
Healthy 3 39 50 3 0 
Moody 0 1 62 32 0 
Patient 1 21 68 5 0 
Irritable 0 0 66 28 1 
Confident 0 6 56 25 8 
Sad 0 3 79 13 0 
Loving 0 0 75 17 3 
Confused 0 0 71 23 1 
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Table 2 
Correlations between Reported Adverse Effects of Ecstasy and the amount the major Psychoactive Drugs consumed in the previous 10 or 30 
days. 
 
 
 Median Inter-quartile 
Range 
Correlation with 
Adverse Reactions 
Measure 
(Spearman’s rho) 
p n 
Amount Consumed (previous 10 
days) 
     
    Ecstasy (tablets) 0 1 -.159 .063 94 
    Alcohol (units) 17 20.5 -.026 .405 89 
    Amphetamine (grams) 0 0 -.044 .340 91 
    Cannabis (joints) 0 2.13 .168 .053 94 
    Cocaine (grams) 0 0 -.001 .497 94 
    Tobacco (cigarettes) 0 77.50 .339 .004 60 
Amount Consumed (previous 30 
days) 
     
    Ecstasy (tablets) 1 4 -.013 .449 93 
    Amphetamine (grams) 0 0 -.044 .340 91 
    Cannabis (joints) 3 24 .115 .139 90 
    Cocaine (grams) 0 1 .048 .340 78 
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Table 3 
Correlations between Reported Adverse Effects of Ecstasy and respectively Length of Use and period of Abstinence for the Main Psychoactive 
Drugs 
 
 
 Median Inter-quartile 
Range 
Correlation with 
Adverse Reactions 
Measure 
(Spearman’s rho) 
p n 
      
Length of use (weeks):      
    Ecstasy 152 163 .237 .011 94 
    Alcohol 372 156 -.029 .392 93 
    Amphetamine 128 216 .103 .284 33 
    Cannabis 266 193 .098 .199 76 
    Cocaine 120 132 .107 .184 73 
    Tobacco 380 194 .159 .099 67 
Weeks since last use:      
    Ecstasy 3 11 .026 .402 94 
    Alcohol 0.14 0.22 -.112 142 93 
    Amphetamine 24 96 .107 .277 33 
    Cannabis 0.57 2.86 -.175 .065 76 
    Cocaine 3 13.14 .011 .465 73 
    Tobacco 0.01 0.14 -.135 .137 67 
      
Number of Different Illicit Drugs 
Consumed 
3 1 .190 .033 94 
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Table 4 
Correlations between Reported Adverse Effects of Ecstasy and respectively Measures of Intelligence and Executive Functioning 
 
 Median Inter-quartile 
Range 
Correlation with 
Adverse Reactions 
Measure 
(Spearman’s rho) 
p n 
Intelligence      
    Ravens Progressive Matrices 48.5 8 -.184 .038 94 
    NART 28 9 -.020 .426 94 
    Analogical Reasoning 12.5 8.75 -.283 .038 40 
    Emotional Intelligence 120 15.75 -.329 .005 60 
    Processing Speed -0.08 0.79 .007 .480 55 
    Processing Speed (errors) -0.10 0.71 .216 .057 55 
Executive Functioning      
    Computation Span (updating) 4 3 .014 .446 94 
    Letter Updating 3.92 1.12 .007 .481 55 
    Plus-Minus (switching) 1.43 0.38 -.023 .441 43 
    Number-Letter (switching) 1.64 0.29 .235 .064 43 
    Letter Fluency (access) -.050 1.27 .161 .207 28 
    Semantic Fluency (access?) -.130 1.50 -.210 .141 28 
    Random Letter Generation  
    (inhibition) 
-0.10 0.53 -.078 .230 93 
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Table 5 
Correlations between Reported Adverse Effects of Ecstasy and Measures of Real World memory  
 
 Median Inter-quartile 
Range 
Correlation with 
Adverse Reactions 
Measure 
(Spearman’s rho) 
p n 
Everyday Memory 91 44 .212 .060 55 
Cognitive Failures (self-report) 45 20 .130 .165 58 
Cognitive Failures (other-report) 13 13 .179 .152 35 
Prospective Memory (Total) 2.47 1.05 .267 .038 45 
      Long Term 2.64 1.46 .191 .105 45 
      Short Term 1.14 0.57 .290 .027 45 
      Internally Cued    2.80 1.36 .121 .215 45 
     Techniques 2.71 2.04 .232 .063 45 
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Table 6 
Correlations between Reported Adverse Effects of Ecstasy and respectively Measures of Sleep Quality, Tiredness, Health, and Psychological 
Affect 
 
 Median Inter-quartile 
Range 
Correlation with 
Adverse Reactions 
Measure 
(Spearman’s rho) 
p n 
      
Sleep Type (Morning or Evening) 4 1 -.022 .415 95 
Sleep Quality 2 1 .194 .030 95 
Hours sleep per night 8 2 -.076 .231 95 
Morning Alertness 3 1 .275 .004 95 
Epworth Daytime Sleepiness 6 5 .174 .047 93 
Karolinska Daytime Sleepiness 
(start of testing) 
5 2 .202 .057 63 
Karolinska Daytime Sleepiness 
(end of testing) 
5.5 3 .344 .003 62 
Arousal 20 5.5 -.264 .005 93 
      
General Health (Self Report)  4 1 -.298 .002 95 
      
Anxiety 12 6 .414 .000 93 
Hedonic Tone/Depression 13 4 .329 .001 93 
 
 
